logo
Plus   Neg
Share
Email

Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts

French drug giant Sanofi SA (SNYNF,SNY) said Monday that Praluent or alirocumab, will be made available at a new reduced U.S. list price of $5,850 annually, a 60 percent reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March.

Praluent or alirocumab Injection inhibits the binding of PCSK9 or proprotein convertase subtilisin/kexin type 9 to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL-C levels in the blood. Praluent was developed by Regeneron Pharmaceuticals (REGN) and Sanofi under a global collaboration agreement.

The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs, and represents another step in the companies' efforts to help improve patient affordability and access.

This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.

"We were encouraged to see improvements in accessibility following our collaboration with payers last year to provide more straightforward, affordable access to Praluent, but only some patients had reduced out-of-pocket costs. With today's announcement, we are looking to help bridge that gap, and have now made Praluent available at a price that is approximately 60% lower," said Michelle Carnahan, North America Head of Primary Care Business Unit at Sanofi.

The new, lower-priced Praluent is expected to be available for pharmacies to order in early March, and the doses with the original list price will remain on the market at least through 2019. The lower-priced Praluent will be identical to the Praluent currently available, other than the list price.

With the new lower-priced Praluent, most Medicare Part D patients are expected to pay between $25 to $150 per month, a potential savings of up to $345, depending on their insurance plan. Eligible commercial patients will continue to have access to co-pay assistance through MyPraluent, Sanofi said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Canada has apologized after a Christmas sweater featuring Santa Claus and apparently cocaine was posted for sale on the company's Canadian website. The retail giant pulled the controversial sweater from its website following a backlash on social media. However, the sweater was not available on Walmart's U.S. website. Ford Motor Co. is recalling around 262 thousand F-Series heavy-duty pickups in the U.S. and Canada citing problem with the electric tailgates that may open unintentionally. The recall involves F-250, F-350 and F-450 Super Duty trucks from the 2017 through 2019 model years. Of these, 231,664 vehicles are in the U.S., while 29,953 are in Canada. Sony's 'MLB The Show' video game series will be available on additional console platforms beyond PlayStation as early as 2021. Currently, the game series is exclusive to PlayStation. 'MLB The Show' is the MLB's officially licensed simulation baseball video game series. San Diego Studio has been creating the officially licensed baseball video games enjoyed by fans for more than 20 years.
Follow RTT
>